Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis Who Failed Second-line Therapy

NCT05524155 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT05524155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05524155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis Who Failed Second-line Therapy
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2022
Completion date
December 31, 2024
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, liver metastasis